ZACKS RESEARCH

FUNDS

PORTFOLIO

BROKER RESEARCH

MARKETS

SCREENING

EDUCATION

SERVICES

Earnings

EPS Surprises

Mutual Funds

Options

My Account

Help

Self Investors Wanted Today

Few spots available. Master Zacks' market-tripling Stock Picking Method in your home at our cost.
Opportunity ends Saturday, Nov. 21 >>

Quote:

Search for Ticker

Free Membership

Search:

BIIB: Biogen Idec Inc - Full Company Report Enter Ticker:

Quote	Estimates	Charts	Company Reports	News	Financials

Full Company Report \| Estimates \| Brokerage Recommendations \| Comparison to Industry \| Insiders \| Brokerage Reports \| Zacks Equity Research \| Annual Report

BIOGEN IDEC INC (NASD)
BIIB	46.38	0.53	(1.16%)	Vol. 2,829,055	16:00 ET

IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases. Their first commercial product, Rituxan, and our most advanced product candidate, ZEVALIN, are for use in the treatment of certain B-cellnon-Hodgkin's lymphomas. They are also developing products for the treatment of various autoimmune diseases (such as psoriasis, rheumatoidarthritis and lupus).

General Information

BIOGEN IDEC INC

14 Cambridge Center Cambridge, MA 02142 Phone: 617 679-2000 Fax: 617-679-2617 Web: www.idecpharm.com Email: idecir@idecpharm.com

Industry	MED-BIOMED/GENE
Sector:	Medical

Fiscal Year End	December
Last Reported Quarter	09/30/09
Next EPS Date	02/05/2010

Price and Volume Information

Zacks Rank
Yesterday's Close	45.85
52 Week High	55.34
52 Week Low	39.01
Beta	0.56
20 Day Moving Average	4,478,021.00
Target Price Consensus	49.56

% Price Change
4 Week	5.87
12 Week	-7.11
YTD	-2.62

% Price Change Relative to S&P 500
4 Week	4.72
12 Week	-12.43
YTD	-19.41

Share Information
Shares Outstanding (millions)	288.86
Market Capitalization (millions)	13,397.14
Short Ratio	3.79
Last Split Date	01/18/2001

Dividend Information
Dividend Yield	0.00%
Annual Dividend	$0.00
Payout Ratio	0.00
Change in Payout Ratio	0.00
Last Dividend Payout / Amount	NA / $0.00

EPS Information
Current Quarter EPS Consensus Estimate	1.06
Current Year EPS Consensus Estimate	3.93
Estimated Long-Term EPS Growth Rate	9.30
Next EPS Report Date	02/05/2010

Consensus Recommendations
Current (1=Strong Buy, 5=Strong Sell)	3.08
30 Days Ago	2.96
60 Days Ago	2.96
90 Days Ago	2.89

Fundamental Ratios

P/E
Current FY Estimate:	11.79
Trailing 12 Months:	12.27
PEG Ratio	1.26

EPS Growth
vs. Previous Year	14.74%
vs. Previous Quarter	49.32%

Sales Growth
vs. Previous Year	2.52%
vs. Previous Quarter:	2.49%

Price Ratios
Price/Book	2.03
Price/Cash Flow	8.89
Price / Sales	3.10

ROE
09/30/09	17.89
06/30/09	17.88
03/31/09	19.40

ROA
09/30/09	12.66
06/30/09	12.41
03/31/09	13.28

Current Ratio
09/30/09	3.57
06/30/09	3.41
03/31/09	3.07

Quick Ratio
09/30/09	3.18
06/30/09	3.08
03/31/09	2.74

Operating Margin
09/30/09	25.54
06/30/09	24.84
03/31/09	26.75

Net Margin
09/30/09	28.55
06/30/09	27.04
03/31/09	28.97

Pre-Tax Margin
09/30/09	28.55
06/30/09	27.04
03/31/09	28.97

Book Value
09/30/09	22.84
06/30/09	21.64
03/31/09	20.25

Inventory Turnover
09/30/09	1.42
06/30/09	1.51
03/31/09	1.54

Debt-to-Equity
09/30/09	0.16
06/30/09	0.17
03/31/09	0.18

Debt to Capital
09/30/09	14.13
06/30/09	14.81
03/31/09	15.24


About Zacks \| Advertise \| Media \| Careers \| Contact Us \| Help Disclaimer \| Privacy Policy \| Sitemap NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed. Copyright 2009 Zacks Investment Research